For months, doctors, pharmacists, and responsible healthcare professionals in South Africa have been raising concerns about the growing flood of unregistered peptide and GLP-1 products being marketed online, in WhatsApp groups, on social media, and even through certain clinics and pharmacies. Now, the South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC) have officially begun stepping in.
The announcement follows a joint investigation into the alleged unlawful manufacturing and distribution of GLP-1 and GIP medicines promoted for weight loss. For many patients who may still feel confused by the terminology surrounding peptides, compounded medications, and weight-loss injections, this latest statement serves as an important reminder: not all injectable GLP-1s, GIPs and Peptides being sold in South Africa are regulated, tested, or safe.
Earlier this year, Aesthetic Appointment Journal published an educational guide on peptides and the increasing concerns around unregulated products entering the South African market. At the time, the aim was not fear-mongering or protecting commercial interests, but rather helping patients understand the difference between medically regulated treatment and products being manufactured or sold outside the law.
SAHPRA’s statement on 23 May 2026 reinforces many of those same concerns. It also highlights a broader regulatory focus on the manufacture, compounding, distribution, and promotion of injectable medicines in South Africa, particularly where questions around compliance, quality assurance, and patient safety may arise.
According to SAHPRA, inspectors seized injectable GLP-1 and GIP products during a recent investigation into activities involving the manufacture and distribution of these medicines. The regulator alleges that medicines containing semaglutide, tirzepatide, and combination formulations were being manufactured and distributed outside the legal framework permitted under South African law.
SAHPRA has indicated that it is increasing regulatory oversight in this area, with many healthcare professionals hoping that wider inspections and investigations, not only of the facility referenced in the statement but across the sector more broadly, will continue wherever concerns around compliance, quality, and patient safety exist.
What are GLP-1 and GIP medicines?
GLP-1 and GIP medicines are prescription medications used to help regulate appetite, blood sugar, metabolism, and feelings of fullness after eating.
GLP-1 stands for glucagon-like peptide-1, while GIP stands for glucose-dependent insulinotropic polypeptide. Both are natural hormones already produced in the body that help regulate hunger, insulin, digestion, and blood sugar control.
Many of these medications were originally developed and approved for the treatment of type 2 diabetes. More recently, certain GLP-1 medications have also received FDA approval for weight management and obesity treatment under proper medical supervision.
Some modern medications work by mimicking one or both of these hormones to help patients feel fuller for longer, reduce appetite, improve blood sugar control, and support medically supervised weight management.
Well-known FDA-approved medications such as Ozempic, Wegovy, and Mounjaro are examples of regulated pharmaceutical products that have undergone extensive clinical testing, quality control, safety monitoring, and manufacturing oversight. Like any prescription medication, these treatments should only be used under the guidance of a qualified healthcare professional.
Over the past two years, demand for GLP-1 medications has surged globally, particularly through social media hype, celebrity influence, and growing public interest in rapid weight loss.
Unfortunately, this has also fuelled a growing market of unregulated products being sold outside proper medical and regulatory systems.
Why medical supervision matters
One of the biggest misconceptions surrounding peptides, such as GLP-1 medications, is that they are simply “weight-loss injections” that anyone can buy and use without proper oversight.
In reality, these are prescription medicines that should be carefully prescribed and monitored by qualified healthcare professionals. Much like antibiotics, blood pressure medication, or hormonal treatment, the value of medical care lies not only in the medication itself, but in the doctor’s knowledge, assessment, monitoring, and ability to prescribe treatment safely and appropriately for each individual patient.
Doctors prescribing these medications are not “selling” miracle weight-loss products. Their role is to properly assess whether treatment is appropriate, evaluate medical history and underlying conditions, monitor for side effects and complications, adjust treatment safely over time, and provide ongoing medical supervision.
This is why healthcare professionals continue to warn patients against buying injectable medications from unverified online sellers, social media accounts, gyms, wellness groups, or individuals without proper medical oversight.
Buying injectable medication from someone like a gym instructor, online reseller, or unofficial supplier may place patients at significant risk and even death, particularly if the product is counterfeit, contaminated, improperly stored, unlawfully imported, incorrectly dosed, or not medically appropriate for that individual.
Simply because a product is labelled as a “peptide” or “GLP-1” does not automatically mean it is regulated, authentic, or safe.
What does “compounded” mean?
Compounding is a legitimate pharmacy practice in certain circumstances. It generally refers to preparing a medicine for an individual patient based on a valid prescription and a specific clinical need.
However, according to SAHPRA, compounding cannot legally be used as a loophole for large-scale manufacturing, advertising, or distribution of unregistered medicines.
In this latest case, SAHPRA states that the facility under investigation was allegedly producing and supplying GLP-1 products beyond what is legally allowed for patient-specific compounding.
The facility has issued a response to SAHPRA’s statement, here. It is important to note that regulatory investigations and legal proceedings are ongoing.
While this investigation has attracted significant attention, many healthcare professionals have pointed out that concerns around unregistered medicines, unlawful compounding practices, questionable imports, and inadequate manufacturing standards are not necessarily limited to a single facility or provider. Regulators worldwide routinely investigate industries where rapid growth creates opportunities for both innovation and non-compliance, and South Africa appears to be no exception.
Why is SAHPRA concerned?
One of the biggest concerns with unregistered injectable medicines is that patients often have no way of verifying exactly what they are receiving, how the product was manufactured, whether it was sterile, or whether the ingredients are authentic and properly tested.
According to SAHPRA, inspectors found serious problems during the investigation, including:
- Alleged illegal importation of active pharmaceutical ingredients (APIs)
- Lack of testing to confirm purity and potency
- Inadequate sterile manufacturing conditions (environments that may not be properly clean or medically controlled)
- Contamination risks (risk of bacteria, impurities, or unsafe substances entering injectable products)
- Insufficient equipment for aseptic preparation (special sterile preparation processes designed to prevent contamination during the making of injectable medicines)
- Absence of proper ventilation systems required for sterile pharmaceutical production (special air filtration and airflow systems needed to safely manufacture injectable medications)
SAHPRA also said that it has received reports of adverse events and hospitalisations linked to some of these products.
Why patients should care
Many patients assume that if a product is being sold by someone in scrubs, promoted on Instagram, or injected in a clinic setting, it must automatically be safe or approved. Unfortunately, that is not always the case.
The peptide and GLP-1 market has become increasingly confusing for consumers. Some products are marketed using vague terms such as “medical grade”, “research peptides”, “custom formulations”, or “compounded wellness injections”, making it difficult for patients to understand what is regulated and what is not.
Patients may also be unaware that:
- Some products sold online may contain unverified ingredients
- Counterfeit or illegally imported products do exist
- Sterile injectable manufacturing requires extremely strict quality controls
- Side effects and complications may not be properly monitored when products fall outside regulated systems
Supporting the doctors who spoke up
Another important aspect of this conversation is recognising that many healthcare professionals who warned patients about unregistered peptide products did so despite criticism, online backlash from people and “influencers” (who illegally sell/buy unregulated peptide medicines), or accusations of protecting financial interests.
In reality, many doctors, pharmacists, and medical professionals have been raising concerns because of patient safety, ethical practice, and growing reports of complications associated with unregulated products.
This latest SAHPRA enforcement action affirms that many of the concerns raised by healthcare professionals warrant careful regulatory review as the “peptide craze” continues to grow. As investigations continue and legal processes unfold, patient safety, transparency, and compliance remain a central issue.
What should patients look out for?
Patients considering GLP-1 or other peptide-based treatments should be asking questions such as:
- Is this product registered with SAHPRA?
- What exactly is being injected?
- Is the medicine sourced through approved pharmaceutical channels?
- Is the prescribing doctor appropriately qualified and supervising treatment? And is the person prescribing this even a doctor?
- Is there proper follow-up and monitoring?
- Can the seller/clinic clearly explain potential side effects and risks?
Patients should also be cautious of:
- Products sold directly through social media
- “Miracle weight loss” claims
- Injectable medications without proper consultations
- Unusually cheap pricing
- Products with unclear labelling or no traceable manufacturer information
The bigger picture
The growing popularity of GLP-1 and other peptide-based medicines has undeniably changed the landscape of obesity medicine, metabolic health, and weight management. Many properly regulated treatments prescribed under medical supervision can offer significant benefits for suitable patients.
However, as demand rises, so does the risk of opportunistic and unlawful activity entering the market.
For patients, the message from SAHPRA is ultimately about safety, transparency, and informed decision-making. And for responsible healthcare professionals who have consistently advocated for regulation and patient protection, this latest statement represents an important moment of validation.
To report fraud, corruption, and unethical behaviour, or to lay complaints relating to medicine and medical devices, the public is encouraged to do so via SAHPRA’s website.
